Loomis Sayles & Co. L P Has $99.61 Million Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Loomis Sayles & Co. L P decreased its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 1.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,243,267 shares of the company’s stock after selling 18,341 shares during the quarter. Loomis Sayles & Co. L P’s holdings in PROCEPT BioRobotics were worth $99,610,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Essex Investment Management Co. LLC grew its stake in PROCEPT BioRobotics by 0.3% during the third quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company’s stock worth $6,489,000 after purchasing an additional 228 shares during the period. Values First Advisors Inc. acquired a new stake in PROCEPT BioRobotics in the third quarter worth $27,000. Arizona State Retirement System raised its holdings in shares of PROCEPT BioRobotics by 2.8% during the second quarter. Arizona State Retirement System now owns 12,840 shares of the company’s stock valued at $784,000 after purchasing an additional 350 shares during the period. KBC Group NV boosted its position in shares of PROCEPT BioRobotics by 32.6% during the 3rd quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after purchasing an additional 376 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of PROCEPT BioRobotics by 4.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company’s stock valued at $606,000 after buying an additional 408 shares during the period. 89.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PRCT shares. Wells Fargo & Company upped their price target on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Jefferies Financial Group began coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective on the stock. Finally, TD Cowen lifted their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.50.

PROCEPT BioRobotics Price Performance

PRCT opened at $93.60 on Monday. PROCEPT BioRobotics Co. has a 1 year low of $33.45 and a 1 year high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average price is $82.41 and its two-hundred day moving average price is $72.53.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $58.40 million for the quarter, compared to analysts’ expectations of $53.30 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm’s revenue for the quarter was up 66.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.51) earnings per share. On average, equities analysts anticipate that PROCEPT BioRobotics Co. will post -1.74 EPS for the current year.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Reza Zadno sold 288,461 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total value of $26,249,951.00. Following the sale, the chief executive officer now owns 258,445 shares of the company’s stock, valued at approximately $23,518,495. The trade was a 52.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin Waters sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $72.47, for a total value of $1,811,750.00. Following the completion of the transaction, the chief financial officer now owns 96,096 shares in the company, valued at approximately $6,964,077.12. The trade was a 20.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 561,773 shares of company stock worth $49,073,125 in the last 90 days. Insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).